Target intelligence / Profile preview

rRNA 2'-O-methyltransferase fibrillarin (FBL)

Target
FBL
Molecular classification
Enzyme, RNA-binding protein, Nucleolar protein, Component of small nucleolar ribonucleoprotein (snoRNP)
01

Overview

Fibrillarin is a highly conserved nucleolar protein composed of 321 amino acids, featuring a glycine-arginine rich (GAR) N-terminal domain and a central methyltransferase domain[1][2][3][4]. It is an essential enzyme in eukaryotes involved in the 2'-O-methylation of ribosomal RNA during pre-rRNA processing as a core component of box C/D small nucleolar ribonucleoproteins (snoRNPs), aiding ribosome biogenesis and overall nucleolar function[1][2][3][4]. Fibrillarin also participates in phase separation dynamics in the nucleolus, and is implicated in cellular homeostasis, reproduction, immune responses, inflammation, and cancer biology[1][2]. It is an autoantigen in autoimmune scleroderma, and aberrant expression or function is associated with malignancy and altered rRNA modification, which has spurred interest in its potential as a therapeutic target in cancer cell biology[1][2][4].

Other names
FBLFIB1FLRNRNU3IP1Nop134 kDa nucleolar scleroderma antigenHistone-glutamine methyltransferaseU6 snRNA 2'-O-methyltransferase fibrillarinFIBRNA U3 small nucleolar interacting protein 134-kD nucleolar scleroderma antigen
02

Mechanism of action

Drugs or molecules targeting FBL would act by inhibiting its methyltransferase activity, modulating rRNA processing, or altering nucleolar phase separation or protein-RNA interactions

03

Biological functions

rRNA 2'-O-methylationPre-rRNA processingRibosome biogenesisNucleolar phase separationCellular homeostasisRegulation of gene expressionImmune responseReproductionInflammationAutoimmunity
04

Disease associations

CancerAutoimmune disease (scleroderma)Reproductive disordersInflammationInfection
05

Safety considerations

Essential for cell viability, thus targeting FBL may have cytotoxic effectsrisks for immune-mediated adverse effects due to its role as an autoantigenpotential effects on broad cellular processes due to loss of ribosome biogenesis
06

Interacting drugs

None known or approved (as of current knowledge and reported literature)
07

Biomarkers

Autoantibodies against fibrillarin in sclerodermapotential marker in cancer for altered ribosome biogenesis

Beyond the preview

Go deeper on rRNA 2'-O-methyltransferase fibrillarin (FBL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rRNA 2'-O-methyltransferase fibrillarin (FBL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call